REPL

Company Overview — What Does Replimune Group, Inc. Do?

Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts. Replimune Group, Inc. (REPL) is classified as a small-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Philip Astley-Sparke and employs approximately 210 people. With a market capitalization of $628M, REPL is one of the notable companies in the Healthcare sector.

Replimune Group, Inc. (REPL) Stock Rating — Hold (April 2026)

As of April 2026, Replimune Group, Inc. receives a Hold rating with a composite score of 30.8/100 and 3 out of 5 stars from the Blank Capital Research quantitative model.REPL ranks #1,782 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Replimune Group, Inc. ranks #182 of 838 stocks, placing it in the top quartile of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

REPL Stock Price and 52-Week Range

Replimune Group, Inc. (REPL) currently trades at $1.75. The stock lost $4.16 (70.4%) in the most recent trading session. The 52-week high for REPL is $13.24, which means the stock is currently trading -86.8% from its annual peak. The 52-week low is $2.68, putting the stock -34.7% above its annual trough. Recent trading volume was 8.2M shares, reflecting moderate market activity.

Is REPL Overvalued or Undervalued? — Valuation Analysis

Replimune Group, Inc. (REPL) carries a value factor score of 23/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 3.06x, versus the sector average of 2.75x.

At current multiples, Replimune Group, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Replimune Group, Inc. Profitability — ROE, Margins, and Quality Score

Replimune Group, Inc. (REPL) earns a quality factor score of 23/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -153.8%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -97.1% versus the sector average of -33.1%.

Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

REPL Debt, Balance Sheet, and Financial Health

Replimune Group, Inc. has a debt-to-equity ratio of 58.0%, compared to the Healthcare sector average of 32.0%. Leverage is within a manageable range for the industry, though investors should monitor debt trends over time. The current ratio is 5.60x, indicating strong short-term liquidity.

REPL has a beta of 0.85, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for Replimune Group, Inc. is 24/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Replimune Group, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Replimune Group, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.77. Net income for the quarter was $-324M. Operating income came in at $-331M.

In Q3 2026, Replimune Group, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.77. Net income for the quarter was $-71M. Operating income came in at $-72M.

In Q2 2026, Replimune Group, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.90. Net income for the quarter was $-83M. Operating income came in at $-84M.

In Q2 2025, Replimune Group, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.90. Net income for the quarter was $-83M. Operating income came in at $-84M.

Over the past 8 quarters, Replimune Group, Inc. has experienced revenue contraction from $0 to $0. Investors analyzing REPL stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

REPL Dividend Yield and Income Analysis

Replimune Group, Inc. (REPL) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

REPL Momentum and Technical Analysis Profile

Replimune Group, Inc. (REPL) has a momentum factor score of 37/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 63/100 reflects moderate short selling activity.

REPL vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Replimune Group, Inc. (REPL) ranks #182 out of 838 stocks based on the Blank Capital composite score. This places REPL in the top quartile of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing REPL against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full REPL vs S&P 500 (SPY) comparison to assess how Replimune Group, Inc. stacks up against the broader market across all factor dimensions.

REPL Next Earnings Date

No upcoming earnings date has been announced for Replimune Group, Inc. (REPL) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy REPL? — Investment Thesis Summary

Replimune Group, Inc. presents a balanced picture with arguments on both sides. The quality score of 23/100 flags below-average profitability. The value score of 23/100 indicates premium valuation. Momentum is weak at 37/100, a headwind for near-term performance. High volatility (stability score 24/100) increases portfolio risk.

In summary, Replimune Group, Inc. (REPL) earns a Hold rating with a composite score of 30.8/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on REPL stock.

Related Resources for REPL Investors

Explore more research and tools: REPL vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare REPL head-to-head with peers: REPL vs AZN, REPL vs SLGL, REPL vs VMD.